Glutamine tract length of human androgen receptors affects hormone-dependent and -independent prostate cancer in mice.
The androgen receptor (AR) is involved in the initiation and progression of prostate cancer and its transition to androgen independence. Genetic variation in AR may contribute to disease risk and has been studied for a polymorphic N-terminal glutamine (Q) tract that shows population heterogeneity. While the length of this tract is known to affect AR in vitro, association with disease is complicated by genetic and environmental factors that have led to discordant epidemiological findings. To clarify the effect of Q tract polymorphism on prostate cancer, we created mice bearing humanized AR genes (h/mAr) varying in Q tract length. ARs with short Q tracts (12Q), which are transcriptionally more active, induce earlier disease in the transgene-induced TRAMP prostate cancer model than alleles with median (21Q) or long (48Q) tracts. Disease length varies within each genotype, with greater differentiation and AR expression in slower growing tumors. Remarkably, following androgen ablation, Q tract length has effects that are also allele-dependent and in directions opposite to those in hormone intact mice. Differences in AR activity conferred by Q tract length thus appear to direct distinct pathways of androgen-independent as well as androgen-dependent progression, and highlight substantial risk that may be associated with alterations in the androgen axis. This AR allelic series in humanized mice provides an experimental paradigm to dissect the role of AR in prostate cancer initiation and progression, to model response to treatment and to test therapies targeted specifically to the human AR.
Albertelli
Megan A
MA
Department of Human Genetics, University of Michigan Medical School, Ann Arbor, MI 48109-0618, USA.
O'Mahony
Orla A
OA
Brogley
Michele
M
Tosoian
Jeffrey
J
Steinkamp
Mara
M
Daignault
Stephanie
S
Wojno
Kirk
K
Robins
Diane M
DM
D000818:Animals; D001483:Base Sequence; D017931:DNA Primers / Q000235:genetics; D005838:Genotype; D006801:Humans; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D009376:Neoplasms, Hormone-Dependent / Q000209:etiology / Q000235:genetics* / Q000378:metabolism*; D009919:Orchiectomy; D010455:Peptides / Q000737:chemistry*; D019048:Prostatic Intraepithelial Neoplasia / Q000209:etiology / Q000235:genetics / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000209:etiology / Q000235:genetics* / Q000378:metabolism*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D012334:RNA, Neoplasm / Q000235:genetics / Q000378:metabolism; D011944:Receptors, Androgen / Q000737:chemistry* / Q000235:genetics* / Q000378:metabolism
C410798:AR protein, human; D017931:DNA Primers; D010455:Peptides; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D011944:Receptors, Androgen; C097188:polyglutamine